Mural Oncology PLC (MURA)
(Delayed Data from NSDQ)
$3.15 USD
-0.02 (-0.63%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $3.14 -0.01 (-0.32%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Mural Oncology PLC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | NA | NA | NA |
Cost Of Goods | 0 | 0 | NA | NA | NA |
Gross Profit | 0 | 0 | NA | NA | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 196 | 185 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -196 | -185 | 0 | 0 | 0 |
Non-Operating Income | 1 | 0 | NA | NA | NA |
Interest Expense | 0 | 0 | NA | NA | NA |
Pretax Income | -195 | -185 | NA | NA | NA |
Income Taxes | 12 | 5 | NA | NA | NA |
Minority Interest | 0 | 0 | NA | NA | NA |
Investment Gains/Losses | 0 | 0 | NA | NA | NA |
Other Income/Charges | 0 | 0 | NA | NA | NA |
Income From Cont. Operations | -207 | -190 | NA | NA | NA |
Extras & Discontinued Operations | 0 | 0 | NA | NA | NA |
Net Income (GAAP) | -207 | -190 | NA | NA | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -194 | -183 | 0 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 3 | 2 | NA | NA | NA |
Income After Depreciation & Amortization | -196 | -185 | 0 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 16.69 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -12.43 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -12.43 | NA | NA | NA | NA |
Fiscal Year end for Mural Oncology PLC falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | NA |
Cost Of Goods | NA | 0.00 | NA | 0.00 | NA |
Gross Profit | NA | 0.00 | NA | 0.00 | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 34.04 | 0.00 | 46.31 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -34.04 | 0.00 | -46.31 | 0.00 |
Non-Operating Income | NA | 3.12 | NA | 0.00 | NA |
Interest Expense | NA | 0.00 | NA | 0.00 | NA |
Pretax Income | NA | -30.92 | NA | -46.31 | NA |
Income Taxes | NA | 0.00 | NA | 4.97 | NA |
Minority Interest | NA | 0.00 | NA | 0.00 | NA |
Investment Gains/Losses | NA | 0.00 | NA | 0.00 | NA |
Other Income/Charges | NA | 0.00 | NA | 0.00 | NA |
Income From Cont. Operations | NA | -30.92 | -59.54 | -51.28 | NA |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | NA |
Net Income (GAAP) | NA | -30.92 | -59.54 | -51.28 | NA |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 16.79 | 16.69 | 16.69 | NA |
Diluted EPS Before Non-Recurring Items | NA | -1.84 | -3.57 | -3.07 | NA |
Diluted Net EPS (GAAP) | NA | -1.84 | -3.57 | -3.07 | NA |